Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Albuvirtide IV Drip vs Injection in Healthy Volunteers
NCT05206019Phase 1Completed
- Sponsor
- Frontier Biotechnologies Inc.
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of albuvirtide in human immunodeficiency virus type 1 infection (HIV-1) (3 cohorts), sponsored by Frontier Biotechnologies Inc. Primary endpoints: Area under curve, Peak concentration and 2 more. Started Feb 2022; status: completed.
02
Drugs
albuvirtide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05206019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206019.